Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.49 |
| ▸ | RAB9A | P51151 | 7/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.49 |
| ▸ | RELA | Q04206 | 1/20 | 0.49 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.48 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.48 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | FPR2 | P25090 | 1/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17169457 | 0.78 | NPC1 (0.58) | NPC1RAB9ASMN1; SMN2TP53NFKB1 | |
| SCHEMBL7476038 | 0.77 | NOTUM (0.58) | NPC1RAB9ASMN1; SMN2TDP1NOTUM | |
| SCHEMBL7717408 | 0.72 | MEN1 (0.51) | SMN1; SMN2NOTUMALDH1A1MEN1KMT2A | |
| SCHEMBL4413239 | 0.70 | NOTUM (0.47) | NAMPTNOTUMBCHEMEN1KMT2A | |
| SCHEMBL7471354 | 0.69 | CYP2C19 (0.57) | RAB9ASMN1; SMN2NAMPTNOTUMALDH1A1 | |
| SCHEMBL11582206 | 0.68 | TAS1R3 (0.50) | NPC1RAB9ASMN1; SMN2TP53NFKB1 | |
| SCHEMBL366747 | 0.68 | SMN1; SMN2 (0.74) | NPC1RAB9ASMN1; SMN2TP53ALDH1A1 | |
| SCHEMBL10472164 | 0.68 | LMNA (0.57) | NPC1RAB9ASMN1; SMN2TDP1NOTUM | |
| SCHEMBL17022633 | 0.68 | NOTUM (0.54) | NPC1RAB9ASMN1; SMN2TP53NFKB1 | |
| SCHEMBL27338591 | 0.67 | TSHR (0.55) | NPC1RAB9ASMN1; SMN2TP53FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050037090-A1 | Combination therapy including a cyclooxygenase-2 inhibitor and an antineoplastic agent | MCKEARN JOHN P (US) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050037090-A1 | Combination therapy including a cyclooxygenase-2 inhibitor and an antineoplastic agent | PTGS2, PTGES2, PTGS1 | NPC1 3863/4885RAB9A 4744/4885SMN1; SMN2 1740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.